Improving cervical cancer screening in Mexico:: Results from the Morelos HPV Study

被引:0
作者
Flores, Y
Bishai, D
Lazcano, E
Shah, K
Lörincz, A
Hernández, M
Salmerón, J
机构
[1] Mexican Inst Social Sercur, Epidemiol & Hlth Serv Res Dept, Cuernavaca, Morelos, Mexico
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] INSP, Ctr Populat Hlth Res, Cuernavaca, Morelos, Mexico
[4] Digene Corp, Gaithersburg, MD USA
[5] Med Coll Georgia, Dept Family Med, Atlanta, GA USA
[6] Johns Hopkins Univ, Sch Med & Hosp, Dept Pathol & Obstet & Gynecol, Baltimore, MD USA
[7] Mexican Inst Social Secur, Reg Hosp, Cuernavaca, Morelos, Mexico
[8] Mexican Inst Social Secur, Epidemiol & Hlth Serv Res Dept, Mexico City, DF, Mexico
来源
SALUD PUBLICA DE MEXICO | 2003年 / 45卷
关键词
cervical cancer; screening; HPV testing; Pap;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. The purpose of this paper is to describe some of the results of the Morelos HPV Study. The main objective of the Morelos HPV Study is to evaluate the use of human papillomavirus (HPV) DNA testing, as compared to the Papanicolaou (Pap) test, for cervical cancer (CC) screening. Material and Methods. The Morelos HPV Study is currently being conducted in Mexico, to examine the possibility of using HPV testing for CC screening. The HPV testing of self-collected vaginal and clinician-collected cervical specimens was evaluated as part of this study. The acceptability of the HPV testing of self-collected specimens was compared to that of the Pap test. A cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) was also performed. Results. The Morelos HPV Study results indicate that HPV testing has a greater sensitivity to detect cervical intraepithelial neoplasia (CIN) 2/3 and CC than the Pap test, Our results also indicate an over-all lower acceptability of the Pap test as compared to the self-collected procedure. The results of the CEA and CBA indicate that screening women between the ages of 20-80 for CC using some type of HPV testing is always more cost-effective than screening for CC using the Pap test. Conclusions. Our results suggest that self- and clinician-collected HPV testing could be used in CC prevention programs, as an effective complement or substitute for the Pap test.
引用
收藏
页码:S388 / S398
页数:11
相关论文
共 78 条
[21]   AN EVALUATION OF HUMAN PAPILLOMAVIRUS TESTING FOR INTERMEDIATE-RISK AND HIGH-RISK TYPES AS TRIAGE BEFORE COLPOSCOPY [J].
HATCH, KD ;
SCHNEIDER, A ;
ABDELNOUR, MW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (04) :1150-1157
[22]   Special section on qualitative spatial reasoning - Introduction [J].
Hernandez, D ;
Jungert, E .
JOURNAL OF VISUAL LANGUAGES AND COMPUTING, 1998, 9 (01) :1-3
[23]  
Hernandez-Avila M, 1994, Gac Med Mex, V130, P201
[24]   Evaluation of the cervical cancer screening programme in Mexico:: a population-based case-control study [J].
Hernández-Avila, M ;
Lazcano-Ponce, EC ;
de Ruíz, PA ;
Romieu, I .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1998, 27 (03) :370-376
[25]   Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica [J].
Herrero, R ;
Hildesheim, A ;
Bratti, C ;
Sherman, ME ;
Hutchinson, M ;
Morales, J ;
Balmaceda, I ;
Greenberg, MD ;
Alfaro, M ;
Burk, RD ;
Wacholder, S ;
Plummer, M ;
Schiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (06) :464-474
[26]  
Herrero R, 1996, J Natl Cancer Inst Monogr, P1
[27]   PREVALENCE AND RISK-FACTORS OF GENITAL HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS IN HEALTHY-MALES - A STUDY ON FINNISH CONSCRIPTS [J].
HIPPELAINEN, M ;
SYRJANEN, S ;
HIPPELAINEN, M ;
KOSKELA, H ;
PULKKINEN, J ;
SAARIKOSKI, S ;
SYRJANEN, K .
SEXUALLY TRANSMITTED DISEASES, 1993, 20 (06) :321-328
[28]   PERSISTENT GENITAL HUMAN PAPILLOMAVIRUS INFECTION AS A RISK FACTOR FOR PERSISTENT CERVICAL DYSPLASIA [J].
HO, GYF ;
BURK, RD ;
KLEIN, S ;
KADISH, AS ;
CHANG, CJ ;
PALAN, P ;
BASU, J ;
TACHEZY, R ;
LEWIS, R ;
ROMNEY, S .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (18) :1365-1371
[29]  
Koutsky Laura, 1997, American Journal of Medicine, V102, P3
[30]  
Lazcano-Ponce E, 2001, INT J CANCER, V91, P412, DOI 10.1002/1097-0215(20010201)91:3&lt